ChemoMetec (Denmark) Performance
| CHEMM Stock | DKK 473.60 6.40 1.33% |
On a scale of 0 to 100, ChemoMetec holds a performance score of 7. The firm shows a Beta (market volatility) of -0.0956, which signifies not very significant fluctuations relative to the market. As returns on the market increase, returns on owning ChemoMetec are expected to decrease at a much lower rate. During the bear market, ChemoMetec is likely to outperform the market. Please check ChemoMetec's standard deviation, expected short fall, period momentum indicator, as well as the relationship between the maximum drawdown and rate of daily change , to make a quick decision on whether ChemoMetec's price patterns will revert.
Risk-Adjusted Performance
7 of 100
Weak | Strong |
OK
Compared to the overall equity markets, risk-adjusted returns on investments in ChemoMetec AS are ranked lower than 7 (%) of all global equities and portfolios over the last 90 days. In spite of rather weak fundamental indicators, ChemoMetec exhibited solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 150.1 M | |
| Total Cashflows From Investing Activities | -56 M |
ChemoMetec |
ChemoMetec Relative Risk vs. Return Landscape
If you would invest 37,300 in ChemoMetec AS on September 2, 2024 and sell it today you would earn a total of 10,060 from holding ChemoMetec AS or generate 26.97% return on investment over 90 days. ChemoMetec AS is generating 0.4594% of daily returns and assumes 4.6515% volatility on return distribution over the 90 days horizon. Simply put, 41% of stocks are less volatile than ChemoMetec, and 91% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
ChemoMetec Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for ChemoMetec's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as ChemoMetec AS, and traders can use it to determine the average amount a ChemoMetec's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0988
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | CHEMM | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 4.65 actual daily | 41 59% of assets are more volatile |
Expected Return
| 0.46 actual daily | 9 91% of assets have higher returns |
Risk-Adjusted Return
| 0.1 actual daily | 7 93% of assets perform better |
Based on monthly moving average ChemoMetec is performing at about 7% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of ChemoMetec by adding it to a well-diversified portfolio.
ChemoMetec Fundamentals Growth
ChemoMetec Stock prices reflect investors' perceptions of the future prospects and financial health of ChemoMetec, and ChemoMetec fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on ChemoMetec Stock performance.
| Return On Equity | 0.49 | |||
| Return On Asset | 0.31 | |||
| Profit Margin | 0.39 % | |||
| Operating Margin | 0.50 % | |||
| Current Valuation | 14.38 B | |||
| Shares Outstanding | 17.4 M | |||
| Price To Earning | 197.96 X | |||
| Price To Book | 40.83 X | |||
| Price To Sales | 32.10 X | |||
| Revenue | 428.39 M | |||
| EBITDA | 224.86 M | |||
| Cash And Equivalents | 209.02 M | |||
| Cash Per Share | 12.01 X | |||
| Total Debt | 6.79 M | |||
| Debt To Equity | 0.02 % | |||
| Book Value Per Share | 26.27 X | |||
| Cash Flow From Operations | 176.86 M | |||
| Earnings Per Share | 10.15 X | |||
| Total Asset | 501.27 M | |||
| Retained Earnings | 36 M | |||
| Current Asset | 33 M | |||
| Current Liabilities | 8 M | |||
About ChemoMetec Performance
By analyzing ChemoMetec's fundamental ratios, stakeholders can gain valuable insights into ChemoMetec's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if ChemoMetec has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if ChemoMetec has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
ChemoMetec AS engages in the development, production, and sale of analytical equipment for cell counting and analysis the United States, Canada, Europe, and internationally. The company was founded in 1997 and is headquartered in Allerd, Denmark. ChemoMetec operates under Medical Equipment classification in Denmark and is traded on Copenhagen Stock Exchange. It employs 155 people.Things to note about ChemoMetec AS performance evaluation
Checking the ongoing alerts about ChemoMetec for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for ChemoMetec AS help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| ChemoMetec AS had very high historical volatility over the last 90 days |
- Analyzing ChemoMetec's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether ChemoMetec's stock is overvalued or undervalued compared to its peers.
- Examining ChemoMetec's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating ChemoMetec's management team can have a significant impact on its success or failure. Reviewing the track record and experience of ChemoMetec's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of ChemoMetec's stock. These opinions can provide insight into ChemoMetec's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for ChemoMetec Stock analysis
When running ChemoMetec's price analysis, check to measure ChemoMetec's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ChemoMetec is operating at the current time. Most of ChemoMetec's value examination focuses on studying past and present price action to predict the probability of ChemoMetec's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ChemoMetec's price. Additionally, you may evaluate how the addition of ChemoMetec to your portfolios can decrease your overall portfolio volatility.
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Stocks Directory Find actively traded stocks across global markets | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Bonds Directory Find actively traded corporate debentures issued by US companies |